norovirus
import
caus
nonbacteri
epidem
gastroenter
specif
antivir
therapi
avail
investig
inhibitori
effect
phosphorodiamidi
morpholino
oligom
pmo
target
noroviru
sequenc
panel
peptideconjug
pmo
ppmo
specif
murin
noroviru
mnv
genom
develop
two
ppmo
compound
direct
first
aug
code
sequenc
near
genom
prove
effect
inhibit
mnv
replic
cell
consensu
ppmo
design
noro
design
target
correspond
region
sever
divers
human
noroviru
genotyp
decreas
effici
protein
translat
cellfre
luciferas
report
assay
inhibit
norwalk
viru
protein
express
repliconbear
cell
data
suggest
ppmo
direct
rel
conserv
noroviru
genom
may
show
broad
antivir
activ
genet
divers
group
virus
norovirus
import
caus
nonbacteri
epidem
gastroenter
age
group
second
import
caus
sporad
endem
diarrhea
infant
young
children
rotavirus
glass
et
al
green
current
vaccin
specif
antivir
therapi
control
noroviru
diseas
green
norovirus
belong
famili
calicivirida
consist
four
genera
noroviru
sapoviru
vesiviru
lagoviru
nm
nonenvelop
virus
singlestrand
positivesens
rna
genom
noroviru
genom
organ
three
open
read
frame
orf
termin
encod
larg
polyprotein
process
matur
nonstructur
protein
green
encod
major
capsid
protein
termin
encod
minor
structur
protein
genu
noroviru
divid
five
differ
genogroup
design
gi
gv
genogroup
ii
iv
includ
human
norovirus
subdivid
sever
genotyp
base
similar
capsid
gene
zheng
et
al
norovirus
highli
variabl
genom
nucleotid
diverg
genogroup
distinct
virus
identifi
date
sequenc
viru
one
conserv
region
among
noroviru
genom
like
calicivirus
noroviru
genom
share
sequenc
similar
viral
subgenom
rna
map
near
begin
green
vaccin
develop
imped
lack
cell
cultur
system
propag
human
norovirus
absenc
vitro
propag
techniqu
compens
somewhat
avail
recombin
viruslik
particl
vlp
produc
express
baculoviru
express
system
bertolotticiarlet
et
al
noroviru
vlp
serv
antigen
studi
noroviru
immun
vaccin
candid
est
et
al
altern
approach
studi
noroviru
rna
replic
establish
human
noroviru
repliconbear
cell
line
creat
transfect
plasmid
contain
norwalk
viru
genom
mammalian
cell
line
cell
line
capabl
constitut
express
replic
enzym
nonstructur
protein
allow
studi
rna
replic
provid
platform
screen
antivir
compound
recent
discoveri
mous
immunodefici
mice
led
develop
first
cell
cultur
system
norovirus
wobu
et
al
mnv
share
molecular
properti
norovirus
although
variou
mnv
strain
less
diverg
genom
sequenc
therefor
compris
singl
genotyp
analysi
mnv
genom
identifi
three
open
read
frame
characterist
norovirus
vesivirus
fig
addit
overlap
differ
read
frame
mnv
also
encod
nonstructur
protein
orf
encod
two
protein
present
viral
capsid
replic
dissemin
wildtyp
mice
limit
depend
interferon
mumphrey
et
al
thu
viru
replic
lymph
node
intestin
tissu
vivo
result
clinic
diseas
mice
vitro
grow
effici
dendrit
cell
macrophag
chaudhri
et
al
ward
et
al
wobu
et
al
facilit
studi
viral
gene
express
replic
cytopatholog
antivir
effector
molecul
addit
mnv
noroviru
revers
genet
system
develop
chaudhri
et
al
ward
et
al
studi
investig
use
phosphorodiamidi
morpholino
oligom
pmo
inhibitor
noroviru
replic
pmo
similar
singlestrand
dna
oligonucleotid
contain
base
dna
morpholin
ring
place
deoxyribos
sugar
neutral
backbon
iversen
pmo
uncharg
watersolubl
highli
resist
degrad
host
pmo
bind
mrna
watsoncrick
basepair
reduc
gene
express
steric
blockad
mrna
ghosh
et
al
stein
et
al
summerton
improv
uptak
cell
pmo
conjug
argininerich
cellpenetr
peptid
produc
peptidepmo
ppmo
abe
et
al
dea
et
al
moulton
et
al
pmo
report
effect
inhibitor
number
virus
includ
hepat
b
c
virus
influenza
viru
picornaviru
fmdv
coronaviru
mous
hepat
sar
caliciviru
west
nile
viru
burrer
et
al
dea
et
al
ge
et
al
heintg
et
al
neuman
et
al
smith
et
al
vagnozzi
et
al
wang
et
al
yang
et
al
titer
felin
caliciviru
fcv
vesiviru
significantli
reduc
cell
cultur
treatment
pmo
target
upstream
region
stein
et
al
furthermor
pmo
report
effect
treat
fcv
diseas
kitten
smith
et
al
correspond
sequenc
rel
conserv
within
norovirus
hypothes
region
might
also
function
target
inhibit
noroviru
replic
design
panel
ppmo
direct
select
region
murin
noroviru
genom
addit
develop
ppmo
target
consensu
sequenc
repres
sever
circul
human
noroviru
genotyp
use
recent
avail
assay
test
abil
ppmo
inhibit
viral
protein
synthesi
replic
correspond
homolog
system
studi
identifi
target
site
near
noroviru
genom
may
prove
use
inhibit
viral
translat
replic
specif
ppmo
applic
pmo
basic
studi
noroviru
replic
vitro
anim
model
might
lead
evalu
class
chemic
compound
antivir
drug
prevent
treatment
noroviru
diseas
human
prior
main
object
identifi
ppmo
effect
inhibit
replic
necessari
first
demonstr
ppmo
uptak
raw
macrophag
dose
respons
determin
maximum
dose
ppmo
nontox
cell
fulfil
former
use
flow
cytometri
quantit
measur
uptak
fitclabel
ppmo
cell
incub
fitcppmo
posit
fluoresc
respect
although
two
structur
differ
addit
fitc
label
hydroxyl
group
prevent
direct
comparison
test
ppmo
result
demonstr
effici
doserespons
uptak
peptideconjug
pmo
macrophag
subsequ
identifi
maxim
nontox
dose
ppmo
cytotox
assay
ppmo
design
studi
tabl
fig
nontox
concentr
fig
higher
concentr
ppmo
induc
cytotox
except
ppmo
c
remain
nontox
even
concentr
antivir
effect
ppmo
maximum
nontox
concentr
see
fig
test
fig
two
ppmo
target
ppmo
b
c
inhibit
viru
replic
least
ppmo
target
terminu
aug
ppmo
significantli
less
inhibitori
expect
ppmo
present
inhibitori
effect
sinc
sequenc
fragment
complimentari
aug
replac
compound
none
compound
target
demonstr
antivir
activ
fig
mnv
ppmoe
h
focus
ppmo
b
c
next
determin
maxim
dose
inhibit
ppmo
fig
screen
antivir
compound
test
maxim
nontox
concentr
ppmo
b
ppmo
c
increas
concentr
control
sequenc
specif
use
compound
e
g
neg
control
control
demonstr
antivir
activ
select
base
similar
ppmo
b
c
nucleotid
length
presenc
pippda
tag
acetyl
group
ppmo
c
inhibit
replic
pfu
viru
ppmo
b
complet
inhibit
replic
pfu
inhibit
sequencespecif
control
compound
effect
prevent
viru
replic
fig
order
compar
potenc
ppmo
b
c
determin
compound
use
pfuwel
base
result
shown
fig
ppmo
b
effect
dose
effect
inhibit
replic
higher
concentr
ppmo
c
requir
inhibit
replic
concentr
compound
effect
inhibit
viral
replic
effect
therefor
compound
effect
inhibit
replic
dose
well
level
cellular
toxic
rel
limit
number
sequenc
avail
circul
norovirus
associ
acut
ill
first
analyz
sequenc
four
noroviru
strain
collect
epidemiolog
survey
hospit
infant
us
zintz
et
al
comparison
new
sequenc
avail
genbank
databas
show
mark
conserv
known
sequenc
howev
norovirus
repres
uniqu
sequenc
align
tabl
use
design
ppmo
design
noro
would
target
consensu
sequenc
repres
predomin
circul
genet
cluster
norovirus
zintz
et
al
base
result
present
previou
data
vesiviru
cell
cultur
system
stein
et
al
examin
whether
region
human
noroviru
genom
might
serv
effect
target
inhibit
pmo
sequenc
virus
well
repres
prototyp
norovirus
indic
tabl
engin
part
nt
leader
sequenc
luciferas
report
plasmid
design
pcineoluc
fig
addit
natur
occur
sequenc
also
design
three
construct
design
laboratori
variant
incorpor
vari
combin
nucleotid
show
evid
variat
among
circul
noroviru
strain
order
test
specif
ppmo
jena
giii
bovin
noroviru
also
includ
analysi
examin
whether
ppmo
noro
show
inhibitori
effect
translat
luciferas
protein
control
leader
sequenc
fig
noro
compound
ad
rang
concentr
translat
reaction
percent
inhibit
calcul
compar
luciferas
express
reaction
nontreat
control
fig
show
percent
inhibit
measur
luciferas
express
level
cellfre
system
ppmo
noro
concentr
inhibit
least
luciferas
express
report
rna
contain
ident
complementari
target
sequenc
addit
inhibit
human
noroviru
construct
bovin
noroviru
target
never
achiev
inhibit
noro
rang
concentr
test
interest
noro
inhibit
translat
two
artifici
laboratori
variant
target
labvar
nucleotid
chang
respect
although
less
effici
giii
bovin
noroviru
genom
contain
nucleotid
chang
precis
noro
target
sequenc
natur
occur
viral
target
ppmo
fail
inhibit
least
luciferas
translat
even
concentr
greater
final
noro
complet
fail
inhibit
translat
third
laboratori
variant
contain
nucleotid
differ
data
shown
order
test
inhibitori
effect
noro
cellular
environ
repliconbear
cell
line
express
norwalk
viru
protein
util
approxim
cell
express
norfolk
viral
protein
observ
immunofluoresc
detect
viral
capsid
protein
fact
togeth
find
peptideconjug
pmo
effici
taken
cell
led
us
choos
electropor
effici
mean
deliv
noro
major
cell
test
proport
cell
incorpor
fitclabel
noro
pmo
follow
electropor
order
examin
effici
transfect
method
fig
major
cell
monolay
show
posit
immunofluoresc
signal
compar
cell
receiv
fitcnoro
pmo
without
electropor
fig
replicon
cell
line
constitut
express
viral
protein
pretreat
pmo
feasibl
reason
highest
nontox
concentr
select
experi
noro
ppmo
introduc
cell
electropor
cell
incub
day
immunofluoresc
assay
perform
antisera
specif
norwalk
viru
protein
rnadepend
rna
polymeras
rdrp
examin
viral
protein
synthesi
level
express
visibl
reduc
presenc
pmo
compar
nontreat
control
cell
fig
express
noroviru
rdrp
protein
also
visibl
reduc
pmotreat
replicon
cell
compar
nontreat
cell
fig
b
result
consist
reduc
translat
viral
protein
noro
human
norovirus
antigen
divers
virus
caus
acut
ill
short
durat
promin
gastrointestin
clinic
manifest
green
presenc
norovirusspecif
serum
antibodi
correl
resist
subsequ
noroviru
infect
ill
lindesmith
et
al
parrino
et
al
complic
impetu
toward
develop
efficaci
vaccin
thu
novel
approach
control
infect
need
howev
design
consider
must
given
fact
virus
also
genet
divers
multipl
genotyp
norovirus
cocircul
worldwid
zheng
et
al
propos
genom
noroviru
classif
system
strain
nomenclatur
divid
norovirus
genogroup
v
genogroup
divid
genet
cluster
genotyp
zheng
et
al
uncorrect
pairwis
distanc
genogroup
unusu
larg
among
rna
virus
rang
genogroup
subdivid
cluster
novgi
novgii
respect
zheng
et
al
scenario
make
select
appropri
vaccin
candid
protect
correl
asid
even
challeng
context
antisens
drug
repres
viabl
altern
prevent
well
treatment
diseas
noroviru
diarrhea
lifethreaten
incapacit
diseas
especi
elderli
immunocompromis
patient
addit
appear
import
sever
diarrhea
infant
young
children
second
rotavirus
regard
import
role
outbreak
nonbacteri
gastroenter
well
known
green
antisens
treatment
shown
effect
clinic
might
therefor
promis
option
variou
group
patient
without
difficulti
mount
effect
immun
respons
murin
noroviru
recent
describ
provid
first
isol
genu
propag
cell
cultur
wobu
et
al
model
offer
opportun
assess
pmo
activ
vivo
wellcharacter
host
speci
result
observ
mous
noroviru
ppmo
test
cell
cultur
show
two
ppmo
target
aug
translat
start
site
inhibit
replic
data
consist
previou
pmo
studi
propos
translat
inhibit
major
mechan
action
ghosh
et
al
stein
et
al
summerton
failur
translat
nonstructur
protein
encod
mnv
genom
would
result
inabl
viru
replic
rna
genom
howev
yet
understood
certain
specif
ppmo
inhibit
viru
growth
eg
ppmo
direct
hypothes
addit
mechan
might
involv
reduct
mnv
infect
beyond
inhibit
translat
ppmo
direct
viru
might
altern
interf
rna
secondari
structur
propos
essenti
viral
rna
replic
simmond
et
al
disrupt
specif
structur
mutagenesi
mnv
genom
report
decreas
viru
titer
fold
simmond
et
al
observ
ppmo
less
effect
viru
replic
ppmo
b
c
unexpect
sequenc
complet
overlap
ppmo
b
two
addit
guanin
nucleotid
length
intermedi
nt
ppmo
b
nt
ppmo
c
nt
compar
studi
mechan
action
ppmo
studi
could
provid
addit
insight
design
optim
antisens
drug
noro
show
broad
rang
inhibit
affect
protein
translat
genet
divers
target
noro
ppmo
treatment
associ
vitro
inhibit
translat
inhibit
pmo
noroviru
target
nucleotid
mismatch
therefor
base
variabl
natur
circul
noroviru
sequenc
found
studi
addit
sequenc
submit
genbank
sinc
design
compound
show
mismatch
less
compar
noro
tabl
noro
potenti
inhibit
translat
everi
human
noroviru
genotyp
describ
far
howev
noro
would
like
inhibit
certain
anim
norovirus
mismatch
bovin
noroviru
mismatch
noro
success
inhibitor
translat
two
variant
test
achiev
inhibit
case
import
properti
noro
sinc
commonli
detect
noroviru
genotyp
worldwid
bull
et
al
kirkwood
result
suggest
efficaci
singl
ppmo
compound
target
conserv
may
affect
mark
genet
variabl
circul
norovirus
region
genom
noro
also
shown
effect
vitro
report
assay
well
toxic
concentr
ppmo
describ
cell
cultur
well
vivo
studi
smith
et
al
vagnozzi
et
al
noro
need
inhibit
total
protein
translat
repres
circul
noroviru
variant
measur
luciferas
report
assay
system
greater
concentr
need
achiev
similar
inhibit
rate
test
artifici
divers
laboratori
variant
bovin
noroviru
case
ppmo
valu
usual
nm
compar
previous
report
valu
patel
et
al
addit
murin
noroviru
ppmo
experi
show
compound
concentr
similar
previous
report
pmo
studi
capabl
inhibit
replic
wide
rang
viru
titer
show
antisens
effect
even
pfu
mnv
presenc
anti
ppmo
ppmo
c
burrer
et
al
ge
et
al
patel
et
al
inhibit
protein
translat
noro
confirm
experi
carri
cell
cultur
noro
effect
inhibit
noroviru
protein
translat
cell
evidenc
immunofluoresc
effect
observ
even
incub
period
noro
concentr
demonstr
stabil
compound
incub
long
period
time
stabil
could
potenti
reduc
number
dose
need
success
treatment
clone
express
norwalk
viru
replicon
constitut
express
norwalk
viru
rna
protein
cell
use
screen
antivir
agent
interferon
alpha
chang
georg
howev
treatment
high
unit
interferon
alpha
concentr
ten
time
ed
significantli
reduc
level
polymeras
protein
yet
approxim
copi
rna
genom
per
cell
retain
antivir
agent
reduct
viral
polymeras
level
directli
correl
reduct
viral
rna
found
signific
reduct
norwalk
protein
treatment
noro
yet
see
signific
reduct
rna
dose
pmo
data
shown
like
viral
polymeras
level
limit
detect
remain
seen
ifna
reduct
viral
rna
may
requir
higher
concentr
compound
observ
relat
natur
infect
await
cell
cultur
method
propag
human
norovirus
indirect
evid
ppmo
b
c
effect
inhibit
viral
genom
replic
context
viru
infect
demonstr
fact
infect
controltr
cell
moi
low
cell
produc
cpe
within
day
ppmo
b
c
treatment
significantli
inhibit
cpe
result
time
dose
moi
time
recent
studi
use
ppmo
inhibit
replic
felin
caliciviru
fcv
norovirusrel
viru
show
antivir
effect
previous
observ
vitro
could
translat
clinic
applic
antivir
strategi
use
similar
test
fcvpmo
mask
first
aug
viru
genom
compound
initi
shown
reduc
fcv
viral
titer
dosedepend
manner
pmo
present
cell
cultur
compar
use
vitro
experi
fcvpmo
test
vivo
administ
subcutan
kitten
outbreak
fcv
diseas
treat
kitten
surviv
sever
fcv
infect
compar
nontreat
kitten
smith
et
al
dosag
use
achiev
result
vivo
estim
approxim
mgkg
studi
implic
current
ppmo
dose
use
murin
human
norovirus
vitro
might
translat
success
clinic
applic
use
antivir
compound
could
repres
huge
advantag
prevent
control
gastroenter
outbreak
durat
clinic
symptom
caus
noroviru
usual
short
selflimit
shed
viru
stool
commonli
last
month
greatli
increas
possibl
transmiss
diseas
green
thu
administr
antivir
sick
patient
contact
might
prevent
spread
diseas
especi
sensit
set
hospit
ward
militari
ship
nurs
home
might
also
prevent
death
elderli
patient
futur
studi
includ
test
ppmo
compound
mnv
mous
model
also
import
investig
whether
escap
variant
might
aris
select
pressur
ppmo
test
ppmo
anim
model
address
import
question
regard
applic
norovirusspecif
ppmo
drug
prevent
control
diseas
human
macrophag
cell
line
atcc
use
propag
cell
cultur
dulbecco
modifi
eagl
medium
dmem
mm
lglutamin
gl
sodium
bicarbon
fetal
bovin
serum
noroviru
replicon
cell
line
express
norwalk
viru
rna
replicon
deriv
human
liver
cell
line
replicon
cell
maintain
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
mgml
neomycin
murin
noroviru
strain
wobu
et
al
provid
herbert
w
virgin
washington
univers
school
medicin
st
loui
mo
viru
receiv
titer
stock
pfuml
use
directli
assay
studi
raw
cell
obtain
american
type
cultur
collect
manassa
va
maintain
dulbecco
modifi
essenti
medium
dmem
fetal
bovin
serum
antibiot
penicillin
unitsml
streptomycin
complet
medium
morpholino
oligom
pmo
synthes
avi
biopharma
inc
corval
pmo
construct
argininerich
peptid
conjug
facilit
cellular
uptak
acetyl
group
ppmo
tabl
show
ppmo
compound
test
studi
eight
differ
ppmo
gener
target
orf
genom
see
fig
addit
sequencenonspecif
fitclabel
ppmo
gener
quantit
cellular
uptak
intracellular
stabil
compound
singl
ppmo
design
target
human
norovirus
orf
noro
see
tabl
noro
also
synthes
gene
tool
philomath
nonconjug
pmo
fluoresceinconjug
pmo
use
noroviru
replicon
cell
cultur
studi
ppmo
pmo
resuspend
steril
distil
water
dilut
dmem
indic
concentr
peptideconjug
pmo
addit
fitc
tag
use
quantit
uptak
ppmo
cell
cell
seed
cell
per
well
plate
incub
overnight
follow
day
cell
rins
twice
dmem
treat
fitcppmo
h
ppmo
remov
cell
rins
twice
plain
dmem
cell
incub
complet
medium
overnight
follow
day
cell
harvest
wash
bd
pharmingen
stain
buffer
bd
bioscienc
san
diego
ca
resuspend
ml
stain
buffer
pass
cell
strainer
sampl
acquir
flow
cytomet
facstar
plu
becton
dickinson
detect
fitc
stain
toxic
assay
develop
order
examin
whether
treatment
cell
ppmo
caus
nonspecif
cytotox
effect
cell
cellswel
seed
flatbottom
plate
follow
day
cell
rins
twice
plain
dmem
incub
h
vari
concentr
ppmo
dilut
plain
dmem
concentr
ppmo
test
replic
eight
follow
incub
cell
rins
twice
dmem
complet
medium
ad
plate
incub
h
follow
day
plate
rins
twice
warm
pb
cell
fix
buffer
formalin
fisher
scientif
fairlawn
nj
overnight
plate
rins
tap
water
dri
overnight
follow
stain
cell
monolay
crystal
violet
plate
rins
extens
left
dri
room
temperatur
follow
day
methanol
ad
per
well
allow
incub
room
temperatur
h
methanoldissolv
stain
transfer
well
clean
plate
plate
read
elisa
plate
reader
biotek
instrument
absorb
nm
averag
absorb
replic
convert
percent
cell
lysi
follow
formula
cell
lysisuntr
pmotreat
untreat
ppmo
test
abil
inhibit
replic
ppmo
inhibit
assay
use
highest
concentr
ppmo
found
nontox
cell
see
briefli
cellswel
seed
flatbottom
plate
follow
day
cell
rins
twice
plain
dmem
ppmo
ad
desir
concentr
eight
replic
well
follow
treatment
ppmo
h
cell
rins
twice
plain
dmem
complet
medium
contain
pfu
ad
well
allow
incub
h
inoculum
remov
follow
one
rins
complet
medium
complet
media
ad
per
well
plate
incub
day
untreat
plate
rins
twice
pb
fix
buffer
formalin
stain
crystal
violet
intens
methanoldissolv
stain
quantit
averag
absorb
nm
replic
convert
percent
cell
lysi
use
follow
formula
cell
lysi
pmotreat
pmotreat
virusinfect
pmotreat
ppmo
inhibit
assay
describ
carri
determin
highest
dose
ppmo
b
ppmo
c
could
effect
inhibit
viral
replic
serial
dilut
rang
pfuwel
pfuwel
indic
use
infect
cell
briefli
cell
treat
ppmo
b
ppmo
c
infect
replic
eight
one
five
dose
ppmo
e
ppmo
g
use
neg
control
untreat
group
repres
cell
incub
dmem
ppmo
infect
one
five
dose
percent
cell
lysi
quantit
follow
formula
ppmo
inhibit
assay
carri
determin
lowest
effect
concentr
ppmo
b
ppmo
c
capabl
inhibit
replic
cell
viru
concentr
remain
constant
pfu
per
well
variou
concentr
ppmo
b
c
rang
replic
eight
use
neg
control
ppmo
e
g
percent
cell
lysi
quantit
use
follow
formula
cell
lysi
pmo
dose
pmotreat
pmotreat
virusinfect
pmotreat
order
design
pmo
target
human
norovirus
avail
genom
sequenc
align
examin
conserv
region
addit
select
repres
circul
noroviru
specimen
epidemiolog
studi
conduct
three
hospit
site
across
us
novemb
decemb
zintz
et
al
partial
genom
sequenc
analysi
stool
sampl
collect
within
h
admiss
frozen
sent
center
pediatr
research
norfolk
virginia
store
screen
rtpcr
onehundr
thirtyf
children
noroviru
ill
identifi
portion
noroviru
genom
sequenc
infect
strain
confirm
noroviru
diagnosi
examin
genet
divers
noroviru
variant
repres
diverg
phylogenet
cluster
collect
select
sequenc
analysi
briefli
race
kit
roch
appli
scienc
indianapoli
use
accord
manufactur
protocol
employ
primer
deduc
relat
virus
belong
genotyp
variant
primer
sequenc
avail
upon
request
abil
ppmo
noro
target
panel
divers
sequenc
evalu
vitro
report
assay
briefli
report
plasmid
engin
includ
sequenc
interest
summar
tabl
translat
leader
sequenc
approxim
nt
length
fuse
frame
immedi
upstream
firefli
luciferas
gene
first
aug
codon
remov
leader
sequenc
synthes
oligonucleotid
engin
restrict
enzym
site
facilit
clone
nhei
sali
site
express
plasmid
pcineo
promega
madison
wi
express
cassett
vector
organ
follow
cmv
promoterinterven
promoterlead
sequenceluciferas
genepolya
signal
fig
construct
verifi
sequenc
analysi
result
plasmid
dna
digest
restrict
enzym
noti
purifi
rna
transcrib
plasmid
polymeras
megascript
ambion
austin
tx
transcrib
rna
purifi
run
agaros
gel
verifi
qualiti
size
addit
rna
quantit
uv
spectroscopi
nm
solut
prepar
use
translat
assay
translat
reaction
carri
rabbit
reticulocyt
lysat
promega
madison
wi
assess
effect
noro
ppmo
translat
reaction
includ
follow
ppmo
final
concentr
rna
final
concentr
nm
amino
acid
mix
nucleasetr
rabbit
reticulocyt
lysat
reaction
incub
min
termin
chill
ice
ten
microlit
reaction
ad
luciferas
assay
reagent
promega
madison
wi
mix
gentli
time
incub
room
temperatur
light
emiss
measur
dynex
mlx
luminomet
dynex
chantilli
va
control
experi
includ
nonspecif
pmo
direct
vesivirus
stein
et
al
ii
nontreat
pmo
iii
specimen
without
rna
noro
ppmo
assay
within
rang
concentr
effect
nontox
previou
cell
cultur
studi
assay
perform
least
twice
construct
analyz
two
independ
investig
two
separ
laboratori
verifi
reproduc
percent
inhibit
determin
compar
reduct
firefli
luciferas
signal
differ
concentr
specif
ppmo
signal
obtain
without
ppmo
well
clone
cell
line
express
selfrepl
noroviru
rna
noroviru
replicon
use
test
noro
pmo
activ
cell
cultur
first
degre
incorpor
pmo
repliconbear
cell
line
assay
use
fluorescein
conjug
noro
pmo
fitcnoro
order
determin
best
electropor
condit
cell
line
optim
kit
util
test
sever
electropor
solut
combin
differ
nucleofect
program
nucleofector
amaxa
gaithersburg
md
electropor
solut
l
combin
nucleofect
program
select
best
compromis
cell
viabil
pmo
incorpor
rang
concentr
fitcnoro
electropor
nucleofector
amaxa
gaithersburg
md
replicon
cell
line
cell
monolay
observ
h
later
fluoresc
determin
toxic
optim
concentr
pmo
base
experi
maximum
concentr
nontox
noro
pmo
electropor
repliconbear
cell
seed
mm
cell
cultur
plate
monolay
incub
day
fix
icecold
methanol
analysi
immunofluoresc
antibodi
rais
guinea
pig
norwalk
viru
polymeras
protein
previous
describ
order
assess
effect
noro
treatment
level
rna
repliconbear
cell
rna
present
treat
untreat
sampl
quantifi
use
singlestep
quantit
realtim
rtpcr
one
taqman
probe
two
primer
specif
amplifi
gi
genotyp
noroviru
genotyp
present
replicon
cell
line
util
liu
moe
briefli
rna
extract
cellsml
use
qiagen
rna
extract
kit
qiagen
valencia
ca
ad
rtpcr
mix
brilliant
ii
q
rtpcr
core
reagent
kit
stratagen
la
jolla
ca
reaction
condit
follow
min
min
follow
cycl
min
abi
ht
real
time
detector
appli
biosystem
foster
citi
ca
appropri
standard
curv
includ
run
murin
noroviru
genom
organ
murin
noroviru
genom
shown
organ
three
differ
open
read
frame
togeth
region
ntr
murin
noroviru
ppmo
target
indic
figur
pmo
synthes
ppmo
direct
arrow
indic
sens
ppmo
shown
partial
overlap
toxic
ppmo
cell
cell
incub
variou
concentr
ppmo
rang
per
ml
indic
replic
untreat
cell
serv
control
follow
treatment
viabl
adher
cell
fix
stain
crystal
violet
methanoldissolv
stain
quantit
elisa
plate
reader
absorb
nm
averag
absorb
replic
convert
cell
lysi
follow
formula
untreat
pmotreat
untreat
pmo
toxic
express
averag
percent
cell
lysi
measur
concentr
error
bar
indic
standard
deviat
quadrupl
measur
ppmo
b
c
inhibit
replic
cell
ppmo
test
abil
inhibit
replic
pmo
inhibit
assay
use
highest
concentr
ppmo
found
nontox
cell
ppmo
ppmo
b
dg
ppmo
c
ppmo
h
cell
treat
h
one
twelv
ppmo
infect
pfu
per
well
three
day
later
cell
fix
stain
methanoldissolv
stain
quantit
absorb
nm
ppmo
assay
control
includ
ppmotreat
cell
viru
virusinfect
cell
ppmo
untreat
inhibit
replic
express
averag
percent
cell
lysi
pmo
error
bar
indic
standard
deviat
quadrupl
measur
effect
load
abil
ppmo
b
ppmo
c
inhibit
viru
replic
cell
determin
highest
dose
ppmo
b
ppmo
c
effect
inhibit
viral
replic
cell
ppmo
inhibit
assay
conduct
serial
dilut
rang
pfuwel
pfuwel
indic
cell
treat
per
ml
ppmo
b
per
ml
ppmo
c
see
fig
infect
pfu
neg
control
ppmo
b
ppmo
e
neg
control
ppmo
c
ppmo
g
untreat
group
repres
cell
incub
dmem
ppmo
infect
one
five
dose
dose
ppmo
done
replic
averag
use
follow
formula
determin
cell
lysi
ppmotreat
ppmotreat
virusinfect
ppmotreat
error
bar
indic
standard
deviat
quadrupl
measur
effect
concentr
abil
ppmo
b
ppmo
c
inhibit
replic
cell
determin
lowest
effect
concentr
ppmo
b
ppmo
c
capabl
inhibit
replic
cell
ppmo
inhibit
assay
conduct
variou
concentr
ppmo
rang
per
ml
indic
untreat
group
repres
cell
incub
dmem
ppmo
infect
pfuwel
neg
control
ppmo
b
ppmo
e
neg
control
ppmo
c
ppmo
g
concentr
ppmo
test
replic
averag
replic
use
follow
formula
cell
lysi
pmotreat
pmotreat
virusinfect
pmotreat
error
bar
indic
standard
deviat
quadrupl
measur
protein
translat
inhibit
noro
ppmo
measur
luciferas
report
assay
inhibitori
activ
noro
sever
target
indic
graph
contain
sequenc
variat
shown
target
result
degre
luciferas
translat
inhibit
plot
compar
bovin
strain
repres
inhibit
luciferas
activ
doserespons
curv
repres
least
independ
repetit
protein
translat
inhibit
experi
target
carri
differ
investig
independ
laboratori
virolog
author
manuscript
avail
pmc
juli
